Search
Menu
Home
Sources
About
Contacts
TM-38837
TM-38837
is a
small molecule
inverse
agonist/antagonist of the
CB
1
cannabinoid receptor
, with
peripheral selectivity
. It is being developed for the
treatment of obesity
and
metabolic disorders
by
7TM
Pharma
. The company has announced
phase I
clinical trials
.
TM-38837 is among the first of a new
generation
of
cannabinoid receptor antagonist
designed to
avoid
the
central nervous system
liabilities
of the
first generation
CB
1
receptor antagonists
such as
rimonabant
.